Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein

Shimeng Bai, Yanxin Cui, Qibin Liao, Hongyang Yi, Zhonghui Liao, Gengwei Zhang, Fenfang Wu, Hongzhou LuViruses 2025 · DOI

TL;DR

Researchers have engineered a novel chimeric protein by fusing the mpox virus (MPXV) A35R protein with the Fc domain of human IgG1. This A35R-Fc fusion protein demonstrates significantly enhanced binding affinity to A35R-specific antibodies and human convalescent plasma compared to the original A35R protein, suggesting its potential as a more effective antigen for next-generation mpox vaccines.

What Problem Does This Paper Address?

The re-emergence of mpox (monkeypox) has highlighted the urgent need for effective prevention and treatment strategies. While existing vaccines offer some protection, they have limitations, including side effects and breakthrough infections. The MPXV A35R protein is a potential target for vaccines, but previous attempts to use it alone have resulted in weak neutralizing antibody responses and limited immunogenicity. This study addresses the challenge of improving the immunogenicity and efficacy of MPXV A35R as a vaccine candidate.

Methods

The core of this research involved protein engineering and immunological assays.

  • Protein Design and Expression: The researchers designed a chimeric protein by genetically fusing the ectodomain of the MPXV A35R protein with the Fc domain of human IgG1. They initially used the native A35R signal peptide but found it led to poor secretion. To overcome this, they replaced it with a tissue plasminogen activator (tPA) signal peptide, which significantly improved the secretion of the recombinant A35R-Fc protein from mammalian cells (HEK293T and CHO-K1).
  • Purification and Characterization: The A35R-Fc protein was purified using Protein A/G affinity chromatography. Its size and structure were confirmed using SDS-PAGE under both reducing and non-reducing conditions, revealing that the Fc domain likely facilitates dimerization.
  • Binding Assays (ELISA & SPR): Enzyme-linked immunosorbent assays (ELISA) and Surface Plasmon Resonance (SPR) were employed to assess the binding affinity of the A35R-Fc protein to A35R-specific antibodies (40886-T62 and RVV13101) and human convalescent plasma samples from individuals infected with MPXV.
  • Immunization and Neutralization Assays: Female BALB/c mice were immunized intramuscularly with either the commercial A35R protein or the A35R-Fc fusion protein, along with adjuvants. Serum samples were collected at various time points to measure anti-A35R antibody titers via ELISA. Crucially, a focus reduction neutralization test (FRNT) was performed to evaluate the ability of the generated antibodies to neutralize live MPXV.

Datasets

This study did not introduce new benchmark datasets. Instead, it utilized:

  • MPXV strain: A specific MPXV strain (hMpxV/China/SZ-SZTH42/2023) isolated from a patient in Shenzhen, China, was used for neutralization assays.
  • Human convalescent plasma: Plasma samples were collected from individuals who had recovered from MPXV infection, including those co-infected with MPXV and HIV. These were used to assess the diagnostic potential of the A35R-Fc protein.

Key Insights and Ideas

  • Fc fusion as a potent immunogenicity enhancer: The study strongly supports the hypothesis that fusing a viral antigen (A35R) to an Fc domain can significantly boost its immunogenicity and binding affinity. This is a well-established strategy in biotherapeutics and is now shown to be effective for MPXV antigens.
  • Improved A35R-Fc affinity: The chimeric A35R-Fc protein demonstrated a markedly enhanced binding affinity to A35R-specific antibodies compared to the non-fused A35R protein. This suggests better recognition by the immune system.
  • Diagnostic potential: The A35R-Fc protein showed good reactivity with human convalescent plasma, indicating its potential utility in serological assays for diagnosing MPXV infection.
  • Enhanced neutralizing antibody response: While the A35R-Fc protein elicited lower IgG titers in ELISA compared to the commercial A35R protein, the sera from A35R-Fc immunized mice were significantly more effective at neutralizing live MPXV. This highlights that antibody quality (neutralizing capacity) can be more important than sheer quantity of IgG.

Key Results

  • The A35R-Fc chimeric protein was successfully constructed, expressed, and purified, showing a band around 40 kDa under reducing conditions and ~100 kDa under non-reducing conditions, consistent with a dimeric Fc fusion.
  • SPR analysis revealed that the affinity of A35R-specific antibodies (40886-T62) to A35R-Fc was increased by approximately 8-fold compared to the commercial A35R protein (KD values of ~0.66 nM for A35R-Fc vs. ~4.88 nM for A35R).
  • A35R-Fc exhibited significant reactivity with most convalescent plasma samples, comparable to the commercial A35R protein.
  • Mice immunized with A35R-Fc generated potent neutralizing antibodies against live MPXV, with an average ID50 of 236.9 four weeks after the second dose, whereas mice immunized with A35R alone did not show significant neutralization.

Limitations and Future Work

  • Discrepancy in ELISA titers: The study noted that the commercial A35R protein elicited higher anti-A35R IgG titers in ELISA than the A35R-Fc, which the authors suggest might be due to the ELISA coating antigen being the commercial A35R. This warrants further investigation into the precise mechanisms.
  • In vivo challenge experiments: While the study demonstrated enhanced neutralizing antibody production, direct in vivo challenge experiments with MPXV are needed to definitively assess the protective efficacy of the A35R-Fc vaccine candidate.
  • Fc effector functions: The authors suggest that the enhanced efficacy of A35R-Fc might be due to improved Fc effector functions (e.g., Fc receptor engagement, ADCC) against the extracellular enveloped virus (EEV). Further research is needed to explore these mechanisms.
  • Optimizing signal peptide: While the tPA signal peptide improved secretion, further optimization of expression and purification strategies could be explored.

Summary updated

Abstract

The re-emergence of the mpox pandemic poses considerable challenges to human health and societal development. There is an urgent need for effective prevention and treatment strategies against the mpox virus (MPXV). In this study, we focused on the A35R protein and created a chimeric A35R-Fc protein by fusing the Fc region of IgG to its C-terminal. We then assessed its reactivity with A35R-specific antibodies and human convalescent plasma, as well as its immunogenicity. Our findings indicate that the A35R-Fc protein significantly enhances affinity to A35R antibodies compared to the commercially available A35R protein and exhibits considerable reactivity to human plasma. Additionally, mice immunized with A35R-Fc exhibited increased neutralizing antibody titers against the live MPXV. These results support the potential of Fc domain chimeric antigens as a strategy to enhance the efficacy of subunit vaccines targeting the MPXV.
BibTeX
@inproceedings{bai2025enhanced,
  author = {Shimeng Bai and Yanxin Cui and Qibin Liao and Hongyang Yi and Zhonghui Liao and Gengwei Zhang and Fenfang Wu and Hongzhou Lu},
  title = {{Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein}},
  booktitle = {Viruses},
  year = {2025},
  doi = {10.3390/v17010116},
}
Figure